STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states

STAT PlusPharmalot Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states Deal is latest settlement in long-running battle between numerous states and many generic makers Manage alerts for this article Email this article Share this article By Ed SilvermanJuly 15, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Glenmark Pharmaceuticals agreed to pay $29.6 million to settle allegations by dozens of states that the company engaged in a widespread conspiracy to artificially inflate and manipulate prices of generic medicines and harmed consumers by reducing competition. The agreement marks the latest settlement in a long-running battle between numerous states and many of the largest players in the generic drug industry, which were accused of fixing prices for their medicines. Previously, Lannett, Bausch, Apotex, and Heritage Pharmaceuticals collectively settled lawsuits for $67 million.Advertisement The litigation began a decade ago amid heightened concern over the cost of prescription medicines, including some generics. The drugs, which have traditionally been lower-cost alternatives to expensive brand-name treatment, account for approximately 90% of all prescriptions written in the U.S. each year. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot July 15, 2026 STAT Plus: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more Pharmalot July 14, 2026 STAT Plus: FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access Advertisement Pharmalot July 14, 2026 STAT Plus: Sales from controversial U.S. drug discount program rose to $100 billion last year Pharmalot July 14, 2026 STAT Plus: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more Pharmalot July 13, 2026 STAT Plus: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents Subscriber Picks